The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients

被引:0
|
作者
Doreen Z. Mhandire
Andrew K. L. Goey
机构
[1] Roswell Park Comprehensive Cancer Center,Department of Pharmacology and Therapeutics
来源
Molecular Diagnosis & Therapy | 2022年 / 26卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Many anticancer drugs cause adverse drug reactions (ADRs) that negatively impact safety and reduce quality of life. The typical narrow therapeutic range and exposure-response relationships described for anticancer drugs make precision dosing critical to ensure safe and effective drug exposure. Germline mutations in pharmacogenes contribute to inter-patient variability in pharmacokinetics and pharmacodynamics of anticancer drugs. Patients carrying reduced-activity or loss-of-function alleles are at increased risk for ADRs. Pretreatment genotyping offers a proactive approach to identify these high-risk patients, administer an individualized dose, and minimize the risk of ADRs. In the field of oncology, the most well-studied gene-drug pairs for which pharmacogenetic dosing recommendations have been published to improve safety are DPYD-fluoropyrimidines, TPMT/NUDT15-thiopurines, and UGT1A1-irinotecan. Despite the presence of these guidelines, the scientific evidence showing the benefits of pharmacogenetic testing (e.g., improved safety and cost-effectiveness) and the development of efficient multi-gene genotyping panels, routine pretreatment testing for these gene-drug pairs has not been implemented widely in the clinic. Important considerations required for widespread clinical implementation include pharmacogenetic education of physicians, availability or allocation of institutional resources to build an efficient clinical infrastructure, international standardization of guidelines, uniform adoption of guidelines by regulatory agencies leading to genotyping requirements in drug labels, and development of cohesive reimbursement policies for pretreatment genotyping. Without clinical implementation, the potential of pharmacogenetics to improve patient safety remains unfulfilled.
引用
收藏
页码:137 / 151
页数:14
相关论文
共 50 条
  • [11] ASSESSMENT OF PATIENTS ADMITTED FOR DRUG-RELATED PROBLEMS IN CANCER CHEMOTHERAPY
    Reji, R. S.
    Kumar, B.
    Nair, S.
    Thunga, G.
    Udupa, K. S.
    VALUE IN HEALTH, 2017, 20 (09) : A412 - A412
  • [12] Impact of DPYD, DPYS, and UPB1 gene variations on severe drug-related toxicity in patients with cancer
    Yokoi, Katsuyuki
    Nakajima, Yoko
    Matsuoka, Hiroshi
    Shinkai, Yasuko
    Ishihara, Takuma
    Maeda, Yasuhiro
    Kato, Takema
    Katsuno, Hidetoshi
    Masumori, Koji
    Kawada, Kenji
    Yoshikawa, Tetsushi
    Ito, Tetsuya
    Kurahashi, Hiroki
    CANCER SCIENCE, 2020, 111 (09) : 3359 - 3366
  • [13] Pharmacogenetics of Anticancer Drug Sensitivity and Toxicity in Colorectal Cancer
    Moradi-Marjaneh, Reyhaneh
    Khazaei, Majid
    Seifi, Sima
    Hassanian, Seyed Mahdi
    Ferns, Gordon A.
    Avan, Amir
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (23) : 2710 - 2718
  • [14] Drug-related problems and the value of a pharmaceutical care service in general surgery patients
    Aburuz, Salah
    Jaber, Deema
    AlAhmad, Mohammad
    Basheti, Iman
    Arafat, Mosab
    Sadeq, Aya
    Said, Amira
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2020, 42 (02) : 817 - 817
  • [15] Drug-Related Problems in Hospitalised Patients
    Patricia M.L.A. van den Bemt
    Toine C.G. Egberts
    Lolkje T.W. de Jong-van den Berg
    Jacobus R.B.J. Brouwers
    Drug Safety, 2000, 22 : 321 - 333
  • [16] Drug-related problems in hospitalised patients
    van den Bemt, PMLA
    Egberts, TCG
    de Jong-van den Berg, LTW
    Brouwers, JRBJ
    DRUG SAFETY, 2000, 22 (04) : 321 - 333
  • [17] Drug-related problems in patients with osteoporosis
    Ilic, Darko
    Bukumiric, Zoran
    Jankovic, Slobodan
    VOJNOSANITETSKI PREGLED, 2016, 73 (03) : 261 - 265
  • [18] Drug-related delirium in elderly patients
    Iglseder, Bernhard
    Dovjak, Peter
    Benvenuti-Falger, Ursula
    Boehmdorfer, Birgit
    Lechleitner, Monika
    Otto, Ronald
    Roller, Regina E.
    Sommeregger, Ulrike
    Gosch, Markus
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 2010, 160 (11-12) : 281 - 285
  • [19] Drug-related mortality in psychiatric patients
    Lynskey, Michael T.
    Kimber, Jo
    Strang, John
    LANCET PSYCHIATRY, 2015, 2 (09): : 767 - 769
  • [20] Strategies to reduce drug-related harm: responding to the evidence base
    Degenhardt, Louisa
    Wolfe, Daniel
    Hall, Wayne
    Hickman, Matthew
    Chang, Judy
    Bruneau, Julie
    Farrell, Michael
    Griffiths, Paul
    LANCET, 2019, 394 (10208): : 1490 - 1493